Cite
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.
MLA
Rammensee, Hans-Georg, et al. “A New Synthetic Toll-like Receptor 1/2 Ligand Is an Efficient Adjuvant for Peptide Vaccination in a Human Volunteer.” Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, Nov. 2019, p. N.PAG. EBSCOhost, https://doi.org/10.1186/s40425-019-0796-5.
APA
Rammensee, H.-G., Wiesmüller, K.-H., Chandran, P. A., Zelba, H., Rusch, E., Gouttefangeas, C., Kowalewski, D. J., Di Marco, M., Haen, S. P., Walz, J. S., Gloria, Y. C., Bödder, J., Schertel, J.-M., Tunger, A., Müller, L., Kießler, M., Wehner, R., Schmitz, M., Jakobi, M., & Schneiderhan-Marra, N. (2019). A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. Journal for ImmunoTherapy of Cancer, 7(1), N.PAG. https://doi.org/10.1186/s40425-019-0796-5
Chicago
Rammensee, Hans-Georg, Karl-Heinz Wiesmüller, P. Anoop Chandran, Henning Zelba, Elisa Rusch, Cécile Gouttefangeas, Daniel J. Kowalewski, et al. 2019. “A New Synthetic Toll-like Receptor 1/2 Ligand Is an Efficient Adjuvant for Peptide Vaccination in a Human Volunteer.” Journal for ImmunoTherapy of Cancer 7 (1): N.PAG. doi:10.1186/s40425-019-0796-5.